North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Size, Share, and COVID-19 Impact Analysis, By drugs (Dulaglutide {Trulicity}, Exenatide {Byetta and Bydureon}, Liraglutide {Victoza}, Lixisenatide {Lyxumia}, and Semaglutide {Ozempic}), By Country (United States, Canada, and rest of North America), and North America Glucagon-Like Peptide-1 (GLP-1) Agonist Market Insights, Industry Trend, Forecasts to 2032.

Industry: Healthcare
RELEASE DATE Jul 2023
REPORT ID SI2448
PAGES 200
REPORT FORMAT PathSoft
Request Free Sample
Description Methodology

Request Free Sample

Your personal details will remain secure and confidential - Privacy Policy

Buy Now

  • Access to only 1 person; cannot be shared; cannot be printed
  • Access for 2 to 5 users only within same department of one company
  • Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

Base Year:2022
Tables & Figures:130
Pages:200
Countries covered:1
Companies covered::10
Forecast CAGR:4.7%
Request Discount

15% Free Customization

Share your Requirements

Request Customization

We Covered in Market

  • 24/7 Analyst Support
  • Worldwide Clients
  • Tailored Insights
  • Technology Evolution
  • Competitive Intelligence
  • Custom Research
  • Syndicated Market Research
  • Market Snapshot
  • Market Segmentation
  • Growth Dynamics
  • Market Opportunities
  • Regulatory Overview
  • Innovation & Sustainability

Connect with us

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies